Last edition
News about "Novartis"
FDA Approves Novartis's Rhapsido as First Oral BTK Inhibitor for Chronic Spontaneous Urticaria
The US Food and Drug Administration (FDA) has approved Novartis’ Rhapsido (remibrutinib) as an oral treatment for adult patients with chronic spontaneous urticaria (CSU) who continue to experience symptoms despite H1 antihistamine therapy.
Novartis | 03/10/2025 | By Dineshwori | 120
Monte Rosa Therapeutics Partners with Novartis on Degraders for Immune Diseases
Monte Rosa to receive an upfront payment of USD 120 million, plus option maintenance payments, and is eligible for option exercise payments and development, regulatory and sales milestones, as well as tiered royalties on global net sales.
Novartis | 16/09/2025 | By Dineshwori | 125
Novartis has entered into a licensing agreement with Monte Rosa Therapeutics valued at up to 5.7 billion USD. The deal centres on developing medicines for immune-mediated diseases, where the immune system mistakenly attacks healthy tissue.
Novartis | 15/09/2025 | By Darshana
Pfizer, Novartis, Roche Lead Net-Zero Pharma Supply Chain Transition
Europe currently dominates the global net-zero pharma supply chain market supported by strict climate regulations, while Asia-Pacific is the fastest-growing region, spurred by new government-led sustainability policies.
Novartis | 11/09/2025 | By Dineshwori | 105
Avanzanite Bioscience Welcomes Dr Mark Bechter as SVP Medical Affairs
Dr Mark Bechter joins Avanzanite Bioscience as SVP of Medical Affairs, marking sixth key leadership hire in 2025 to advance rare disease access across Europe.
Novartis | 10/09/2025 | By Dineshwori
Novartis to Acquire Tourmaline Bio for USD 48 per share
Novartis to acquire Tourmaline Bio in a USD 1.4 billion deal, gaining rights to pacibekitug—an anti-IL-6 antibody with potential in cardiovascular disease; transaction expected to close in Q4 2025.
Novartis | 09/09/2025 | By Dineshwori
Arrowhead and Novartis Sign Global License and Collaboration Deal
Novartis secures exclusive global rights to Arrowhead’s ARO-SNCA therapy for Parkinson’s and related disorders, with Arrowhead receiving USD 200 million upfront.
Novartis | 05/09/2025 | By Dineshwori
Argo Biopharma and Novartis Partner on Novel Cardiovascular Therapies
Argo to receive $160 million upfront as Novartis licenses pipeline assets, explores ANGPTL3 in dyslipidemia, and secures options for future siRNA candidates.
Novartis | 05/09/2025 | By Dineshwori
Biopharma Firms See 5.7 Percent Market Cap Drop in Q2 2025: Globaldata
Twenty biopharmaceutical companies have reported a 5.7 percent quarter-on-quarter (QoQ) downturn in their combined market capitalisation from USD 3.9 trillion on 31 March, 2025 to USD 3.7 trillion on 30 June, 2025.
Novartis | 01/09/2025 | By Dineshwori
This marks the third collaboration BioArctic has entered into with partners using the BrainTransporter technology.
Novartis | 27/08/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy